When a diabetes medication became a cultural phenomenon, the invisible border between Canadian pharmaceutical supply and American consumer demand suddenly became very visible. In early 2023, British Columbia discovered that more than one in seven Ozempic prescriptions filled within its borders were going to Americans — drawn by lower prices and celebrity-fueled weight-loss hype — prompting the province to restrict sales to non-residents and call for federal intervention. The episode is less a story about one drug than about a structural vulnerability Canada has carried for decades: a finite do
B.C. clamps down on Ozempic exports as U.S. demand threatens Canadian drug supplies
Canadian patients risk medication access denial if Ozempic and other essential drugs are diverted to U.S. markets through cross-border sales.
Canada cannot satisfy American appetites for cheaper pharmaceuticals
Mark
Why does Canada have cheaper Ozempic in the first place? Isn't it the same drug made by the same company?
Mimi
It is the same drug. But Canada negotiates drug prices differently than the U.S. does. The American system lets pharmaceutical companies charge whatever the market will bear. Canada's system is more regulated. So the same vial costs less here.
Mark
And the company just accepts that? They don't try to stop Canadians from reselling it south?
Mimi
They can't really stop it once the drug leaves the pharmacy. What they do control is how much they manufacture and ship to Canada in the first place. They only send enough for the Canadian population. If Canadians start exporting it, there's nothing left for Canadians.
Mark
So the real problem isn't the individual Americans buying drugs. It's the scale.
Mimi
Exactly. A few people crossing the border to save money—that's always happened. But when you have online pharmacies shipping thousands of doses to Americans, that's different. That's diversion. That's supply meant for Canadian patients ending up somewhere else.
Mark
Why did this happen with Ozempic specifically?
Mimi
Celebrity endorsement, social media, and the fact that it works for weight loss even though it's approved for diabetes. Demand exploded. And because it's injectable and can be mailed, it was easy to ship. A single practitioner in Nova Scotia was prescribing it to Americans through B.C. pharmacies. That's how visible the problem became.
Mark
Can the government actually stop it by restricting sales?
Mimi
They can make it harder. But the incentive structure doesn't change. As long as Americans can buy Ozempic cheaper in Canada, someone will find a way to sell it to them. The government is trying to close the loopholes, but it's like trying to hold back water.
Mark
What happens if they don't?
Mimi
Canadians who need Ozempic for diabetes can't get it. That's the fear. The supply runs out because it's been diverted to the American market. And then you have a shortage of an essential medication in your own country.
El Pulso
- In just the first two months of 2023, Americans claimed over 15% of B.C.'s Ozempic supply, with thousands of doses mailed south through a single Nova Scotia practitioner — a quiet drain that suddenly became impossible to ignore.
- Celebrity endorsements and social media turned a diabetes medication into a weight-loss sensation, supercharging cross-border demand far beyond anything individual pharmacy tourism had ever produced.
- Online pharmacies shattered the old geographic limits of the problem, enabling continental-scale exportation that pharmaceutical manufacturers have no mechanism — and little incentive — to stop.
- B.C. Health Minister Adrian Dix moved to ban non-resident purchases and pressed Ottawa for national protections, warning that Ozempic was a preview, not an anomaly.
- Canadian diabetic patients now face the real possibility of finding their medication unavailable, because Novo Nordisk ships only enough for the intended domestic population — once that allocation leaves, nothing replaces it.
- Investigators were called in to examine the prescribing practitioner at the center of the trade, but the deeper question remains open: can Canada close regulatory loopholes faster than economic incentives create new ones?
When a diabetes medication became a cultural phenomenon, the invisible border between Canadian pharmaceutical supply and American consumer demand suddenly became very visible. In early 2023, British Columbia discovered that more than one in seven Ozempic prescriptions filled within its borders were going to Americans — drawn by lower prices and celebrity-fueled weight-loss hype — prompting the province to restrict sales to non-residents and call for federal intervention. The episode is less a story about one drug than about a structural vulnerability Canada has carried for decades: a finite domestic supply that cannot hold its ground against the gravitational pull of a far larger, far wealthier market next door.
British Columbia moved this spring to restrict Ozempic sales to non-residents, a decision that laid bare a vulnerability Canadian health officials have warned about for nearly twenty years. In the first two months of 2023, more than 15 percent of Ozempic prescriptions filled in the province went to Americans — many of them prescribed by a single Nova Scotia practitioner and mailed south in bulk. Health Minister Adrian Dix called the situation unacceptable and announced he would seek federal action. "It's Ozempic today, it might be another drug tomorrow," he said.
The drug's rise had been extraordinary. Spending by Canadian drug plans on the injectable leapt from $13.5 million in 2019 to $227 million in 2021. Celebrity endorsements and social media turned a diabetes treatment into a weight-loss phenomenon, and Americans — facing far higher domestic prices — found that Canadian online pharmacies could fill the gap at scale. Novo Nordisk ships only enough product to meet the intended Canadian population's needs; once that supply is diverted south, there is nothing left for the diabetic patients who depend on it.
Brett Skinner of the Canadian Health Policy Institute said B.C.'s move vindicated warnings dating back to the early 2000s. The economics were simple and stubborn: Americans rationally seek the lowest price, Canadian pharmacies can legally fill online orders, and pharmaceutical companies have no incentive to ship extra inventory that would undermine their American pricing structure. Joelle Walker of the Canadian Pharmacists Association drew the key distinction — individual cross-border buyers had never been the real threat; it was large-scale exportation, now made possible by the internet, that could actually drain domestic stock.
Nova Scotia's College of Physicians and Surgeons opened an investigation into the practitioner at the center of the trade, and Novo Nordisk pledged to work with authorities to limit non-resident sales. But the incentives driving the problem remained unchanged. The question facing Canadian policymakers was whether national protections could be built — and built quickly enough — to keep the next drug shortage from following the same path.
British Columbia moved this spring to restrict who could buy Ozempic within its borders, a decision that exposed a problem Canadian health officials have been warning about for nearly two decades: Americans with deeper pockets will always find a way to drain Canadian drug supplies if the price difference is steep enough.
The diabetes medication had become a phenomenon. Celebrities talked about it on social media. Advertisements ran everywhere. People who didn't have diabetes wanted it anyway, drawn by stories of dramatic weight loss. In the first two months of 2023, more than 15 percent of Ozempic prescriptions filled in B.C. went to Americans. Thousands of doses were being mailed across the border, many of them prescribed by a single practitioner in Nova Scotia working through B.C. pharmacies. The situation had become, in the words of Health Minister Adrian Dix, unacceptable.
Dix announced he would push for federal action to stop non-residents from buying the drug in Canada. "It's Ozempic today, it might be another drug tomorrow," he said, "but I don't think this is a short-term thing." The concern was straightforward: Canada's supply of the medication was finite. The American market was not. If the cross-border flow continued unchecked, Canadians who actually needed Ozempic for diabetes would find it unavailable. The manufacturer, Novo Nordisk, ships only enough product to satisfy the intended Canadian population. Once that allocation is diverted south, there is nothing left.
Brett Skinner, founder of the Canadian Health Policy Institute, said the B.C. government's move vindicated warnings he and others had been making since the early 2000s. He understood the economics perfectly: Americans rationally seek the lowest price for the same drug. Pharmaceutical companies rationally refuse to ship extra inventory that might undermine their American pricing structure, which funds their entire business model. Canada, caught in the middle, cannot compete with American demand. The only solution is to restrict who can buy domestically.
The scale of Ozempic's popularity was staggering. Spending by drug coverage plans on the injectable jumped from $13.5 million in 2019 to $227 million in 2021, according to research by the Canadian Agency for Drugs and Technologies and Health. The drug had already caused shortages in other places. B.C. was trying to prevent that from happening at home.
Joelle Walker, vice-president of public and professional affairs for the Canadian Pharmacists Association, distinguished between the old problem and the new one. Individual Americans crossing the border to buy cheaper medications had never been the real concern. What mattered was large-scale exportation—quantities significant enough to actually deplete Canadian stock. Online pharmacies had made that scale possible in ways that hadn't existed before. The internet had turned a local problem into a continental one.
Nova Scotia's College of Physicians and Surgeons was asked to investigate the practitioner whose prescriptions were fueling the cross-border trade. B.C.'s College said it would open an investigative file if patterns of prescribing suggested a registrant wasn't following professional guidelines. Novo Nordisk said it shared the government's interest in protecting B.C.'s supply and would work with authorities to limit sales to non-residents.
What remained unclear was whether these measures would actually work. The problem wasn't a secret anymore. It was visible, quantified, and acknowledged by every player involved. But the incentives hadn't changed. Americans still needed cheaper drugs. Canadian pharmacies could still fill orders online. And as long as the price gap existed, someone would find a way to exploit it. The question now was whether Canada could close the loopholes faster than new ones opened.
Citas Notables
We would never have sufficient supply of Ozempic in British Columbia to satisfy the needs of the American market. We have to protect patients here.— B.C. Health Minister Adrian Dix
It's perfectly rational economic behaviour for consumers to seek the lowest price for the same product, but Canada cannot satisfy American appetites for cheaper pharmaceuticals.— Brett Skinner, Canadian Health Policy Institute
Quieres la nota completa?
Lee el original en Caledonia Courier ↗
Health & Medicine